Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? suptype.

Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ?-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the ?-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.

Abstract: The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: A process for producing high amount of proteins or polypeptides in yeast is disclosed. The process makes use of the CIT1 yeast promoter or a functional part or variant thereof. Examples of polypeptides which are expressed in high yields are insulin or insulin analogues or GLP1.

Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.

Abstract: The invention relates to: A method of providing an electronically readable item of information (725) on a medication cartridge (70). The invention further relates to a cartridge (70) containing an electronically readable item of information (725), a support (75) for reading the information (725) on the cartridge (70), a medication delivery device adapted to use a cartridge (70) and a support (75) according to the invention and a label (72) containing an electronically readable item of information (725). The object of the present invention is to provide an alternative method of generating an electronically readable item of information on a cartridge which method is simple and improves safety in reading. The problem is solved in that said item of information is redundantly provided (725, 726). The invention may e.g. be used in connection with medication delivery devices for self-treatment of a disease, e.g. diabetes.

Abstract: The invention relates to a safety needle assembly for injecting a fluid into a human body comprising a cylindrical housing with a bottom surface supporting a needle cannula and a shield telescopically movable relative to the housing. A spring located within the housing urges the shield in a distal needle covering direction and a locking member also provided inside the housing moves simultaneously with the shield during injection and automatically locks the shield in a position where the sharp end of the needle cannula is concealed thereby irreversible immobilizing the safety needle assembly.

Abstract: A solid composition containing a meiosis activating substance can be prepared by adding a protein or a phosperglycid.

Abstract: Crystals of glucagon-like peptide-1 (GLP-1) and GLP-1 analogues, and processes for preparation of crystals of GLP-1 and GLP-1 analogues.

Abstract: The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration. Factor VIIa administered subcutanously, intramuscularly or intradermally shows a sufficient transport into the bloodstream in biologically active form and in adequate concentrations, and favorable pharmacokinetic properties.

Abstract: Disclosed is a method of preparing zinc free rapid acting insulin analogue. In one embodiment insulin crystals are prepared by providing a solution of an analogue having a pH between 7 and 9.5. The solution is mixed with a salt of an alkali metal or salt and formed crystals are recovered.

Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The modified Factor VII may be used in conjunction with stents to inhibit coagulation, vascular restenosis, and/or platelet deposition.

Abstract: A dose setting device for a delivery system has a piston rod (6, 9) which successively presses a piston (2) into a cylinder ampoule (1). Doses are set by rotating a second part (9) of the piston rod (6, 9) in relation to a first part (6). The two parts are connected by mating threads so that the total length of the piston rod (6, 9) is increased proportional to the angle of rotation, and a point (18) on the second part is moved away from a stop position fixed in relation to a housing (5) The set dose is delivered when the point (18) is moved back to the stop position. The first part (6) can be axially displaced but not rotated in the housing (5), and the second part (9) can both rotate and be axially displaced. The first part (6) is maintained in abutment with the piston (2) and the second part (9) is coupled to be rotated by a dose setting wheel (20).

Abstract: An apparatus for filling a cartridge with a liquid comprises, a platform on which the cartridge is supported and which can be lifted relative to a stationary filling needle (5) so that this filling needle is moved into the cartridge (6), a pump (1) feeding liquid through the filling needle (5) into the cartridge (6), a sensor head (10) from which a beam of light is sent from one side of the cartridge to the other along a path immediately over an upper edge of the cartridge (6), and a reflector (11) reflecting the light beam back to the sensor head (10), which is connected to a sensor box (12) which produces a signal stopping the pump (1) and causing the needle (5) to be drawn out of the cartridge (6) when this cartridge is full and the liquid forms a droplet over the opening of the cartridge, which droplet deflects the light beam.

Abstract: A linear actuator comprising a first member (1) and a second member (2) provided with internal threads (6,8) cut in opposite directions and an intermediary member (3) engaged with and being axially displaceable in relation to the first and second members (1,2), via external threads (11,12) that are complementary to the threads (6,8) provided on the first and second members (1,2). The linear actuator furthermore comprises a sheath (4) stretching across the intermediary member (3), which sheath (4) is inrotatably, but longitudinally slidably arranged in relation to the first and second members (1,2). The linear actuator also comprises a driving rod (5) that is inrotatably, but longitudinally slidably arranged within the intermediary member (3). A medical delivery device provided with such a linear actuator is also provided.

Abstract: A method for preparing a compound of formula I or a salt thereof is disclosed.

Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 Å.

Abstract: The invention relates to novel carbazole derivatives, their use for the preparation of a pharmaceutical composition for the treatment of eating and metabolic disorders such as obesity, bulimia nervosa, anorexia nervosa, of sleep disturbance, of morphine withdrawal symptoms and of epileptic seizures, a pharmaceutical composition containing them and a process for preparing them.